Читать книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов - Страница 289

1 1. Wallis KA. No medicine is sometimes the best medicine. BMJ Case Rep. 2015.

2 2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365(21):2002–12.

3 3. Guthrie B, Makubate B, Hernandez‐Santiago V, Dreischulte T. The rising tide of polypharmacy and drug‐drug interactions: population database analysis 1995‐2010. BMC Med. 2015; 13:74.

4 4. Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug‐drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther. 2007; 45(12):643–53.

5 5. Franchi C, Tettamanti M, Pasina L, et al. Changes in drug prescribing to Italian community‐dwelling elderly people: the EPIFARM‐Elderly Project 2000–2010. Eur J Clin Pharmacol. 2014; 70(4):437–43.

6 6. Gillette C, Prunty L, Wolcott J, Broedel‐Zaugg K. A new lexicon for polypharmacy: Implications for research, practice, and education. Res Social Adm Pharm. 2015; 11(3):468–71.

7 7. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13(1):57–65.

8 8. Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013; 30(5):285–307.

9 9. United States. Congress. Senate. Committee on Finance. Omnibus Budget Reconciliation Act of 1987: explanation of provisions approved by the committee on December 3, 1987 for inclusion in Leadership Deficit Reduction Amendment. Washington: US GPO; 1987:vi.

10 10. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community‐dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012; 65(9):989–95.

11 11. Steinman MA, Miao Y, Boscardin WJ, Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014; 29(10):1379–86.

12 12. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11‐year national analysis. Pharmacoepidemiol Drug Saf. 2010; 19(9):901–10.

13 13. Mannucci PM, Nobili A, Pasina L, Collaborators R. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med. 2018; 13(8):1191–200.

14 14. Doan J, Zakrzewski‐Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450‐mediated drug‐drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013; 47(3):324–32.

15 15. Cepeda OA MJ. Polypharmacy, is it another disease? In: Pathy MS SA, Morley JE, eds. Principles and Practice of Geriatric Medicine. 4th ed. John Wiley & Sons, Ltd; 2006:215–21.

16 16. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med. 2002; 18(3):577–92.

17 17. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross‐sectional and longitudinal study. J Gerontol. 1976; 31(2):155–63.

18 18. David SP. Pharmacogenetics. Prim Care. 2004; 31(3):543–59, ix.

19 19. Brockmoller J, Stingl JC. Multimorbidity, polypharmacy and pharmacogenomics in old age. Pharmacogenomics. 2017; 18(6):515–7.

20 20. American Geriatrics Society. Updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019; 67(4):674–94.

21 21. Curtin D, Gallagher PF, O’Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019; 10.

22 22. Jano E, Aparasu RR. Healthcare outcomes associated with Beers’ Criteria: a systematic review. Ann Pharmacother. 2007; 41(3):438–47.

23 23. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015; 44(2):213–8.

24 24. Anrys P, Boland B, Degryse JM, et al. STOPP/START version 2‐development of software applications: easier said than done? Age Ageing. 2016; 45(5):589–92.

25 25. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008; 37(6):673–9.

26 26. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992; 45(10):1045–51.

27 27. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013; 30(11):893–900.

28 28. Whitman AM, DeGregory KA, Morris AL, Ramsdale EE. A comprehensive look at polypharmacy and medication screening tools for the older cancer patient. Oncologist. 2016; 21(6):723–30.

29 29. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: ‘There’s got to be a happy medium’. JAMA. 2010; 304(14):1592–601.

30 30. Chieng JH, Hughes L, Stewart A, Frampton CM, Hanger HC, Jardine DL. Introduction of the Pill Pruner to acute medical care: a simple medication guide to control polypharmacy. Australas J Ageing. 2015; 34(1):58–61.

31 31. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007; 167(8):781–7.

32 32. Kouladjian L, Gnjidic D, Chen TF, Mangoni AA, Hilmer SN. Drug Burden Index in older adults: theoretical and practical issues. Clin Interv Aging. 2014; 9:1503–15.

33 33. Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med. 2009; 122(12):1142‐9 e1‐2.

34 34. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015; 63(1):85–90.

35 35. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc. 2011; 59(5):875–80.

36 36. Niehoff KM, Rajeevan N, Charpentier PA, Miller PL, Goldstein MK, Fried TR. Development of the Tool to Reduce Inappropriate Medications (TRIM): a clinical decision support system to improve medication prescribing for older adults. Pharmacotherapy. 2016; 36(6):694–701.

37 37. Kuhn‐Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014; 31(2):131–40.

38 38. Pazan F, Weiss C, Wehling M, Forta. The FORTA (Fit fOR The Aged) List 2015: Update of a Validated Clinical Tool for Improved Pharmacotherapy in the Elderly. Drugs Aging. 2016; 33(6):447–9.

39 39. Wehling M, Burkhardt H, Kuhn‐Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016; 45(2):262–7.

40 40. Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence‐based medicine against falls risk. Postgrad Med. 2015; 127(3):330–7.

41 41. Moulis F, Moulis G, Balardy L, et al. Searching for a polypharmacy threshold associated with frailty. J Am Med Dir Assoc. 2015; 16(3):259–61.

42 42. Chiu MH, Lee HD, Hwang HF, Wang SC, Lin MR. Medication use and fall‐risk assessment for falls in an acute care hospital. Geriatr Gerontol Int. 2015; 15(7):856–63.

43 43. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009; 26(12):1039–48.

44 44. Gomez C, Vega‐Quiroga S, Bermejo‐Pareja F, Medrano MJ, Louis ED, Benito‐Leon J. Polypharmacy in the elderly: a marker of increased risk of mortality in a population‐based prospective study (NEDICES). Gerontology. 2015; 61(4):301–9.

45 45. Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010; 123(8):719–26.

46 46. Wright JT, Jr, Whelton PK, Reboussin DM. A randomized trial of intensive versus standard blood‐pressure control. N Engl J Med. 2016; 374(23):2294.

47 47. Ortiz E, James PA. Let’s not SPRINT to judgment about new blood pressure goals. Ann Intern Med. 2016; 165(12):889–90.

48 48. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA. 2015; 314(2):170–80.

49 49. Keeler E, Guralnik JM, Tian H, Wallace RB, Reuben DB. The impact of functional status on life expectancy in older persons. J Gerontol A Biol Sci Med Sci. 2010; 65(7):727–33.

50 50. Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1‐year mortality in older adults after hospitalization. JAMA. 2001; 285(23):2987–94.

51 51. Duncan P, Murphy M, Man MS, Chaplin K, Gaunt D, Salisbury C. Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ). BMJ Open. 2018; 8(4):e019413.

52 52. Schreiner N, Schreiner S, Daly B. The association between chronic condition symptoms and treatment burden in a skilled nursing population. J Gerontol Nurs. 2018; 44(12):45–52.

53 53. Trevena L. Minimally disruptive medicine for patients with complex multimorbidity. Aust J Gen Pract. 2018; 47(4):175–9.

54 54. Bohlen K, Scoville E, Shippee ND, May CR, Montori VM. Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters. Diabetes Care. 2012; 35(1):47–9.

55 55. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015; 175(5):827–34.

56 56. Potter K, Flicker L, Page A, Etherton‐Beer C. Deprescribing in frail older people: a randomised controlled trial. PLoS One. 2016; 11(3):e0149984.

57 57. van der Cammen TJ, Rajkumar C, Onder G, Sterke CS, Petrovic M. Drug cessation in complex older adults: time for action. Age Ageing. 2014; 43(1):20–5.

58 58. Salonoja M, Salminen M, Vahlberg T, Aarnio P, Kivela SL. Withdrawal of psychotropic drugs decreases the risk of falls requiring treatment. Arch Gerontol Geriatr. 2012; 54(1):160–7.

59 59. van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Risk of falls after withdrawal of fall‐risk‐increasing drugs: a prospective cohort study. Br J Clin Pharmacol. 2007; 63(2):232–7.

60 60. Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol. 2001; 51(3):257–65.

61 61. Page A, Etherton‐Beer C. Undiagnosing to prevent overprescribing. Maturitas. 2019; 123:67–72.

62 62. Leijten FRM, Hoedemakers M, Struckmann V, et al. Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. BMJ Open. 2018; 8(8):e021072.

63 63. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J. 2015; 45(3):352–6.

64 64. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence‐based, patient‐centred deprescribing process. Br J Clin Pharmacol. 2014; 78(4):738–47.

65 65. Barnett NL, Oboh L, Smith K. Patient‐centred management of polypharmacy: a process for practice. Eur J Hosp Pharm. 2016; 23(2):113–7.

66 66. Todd A, Jansen J, Colvin J, McLachlan AJ. The deprescribing rainbow: a conceptual framework highlighting the importance of patient context when stopping medication in older people. BMC Geriatr. 2018; 18(1):295.

67 67. Armor RH. A tool to evaluate polypharmacy in elderly persons. Annals of Long Term Care. 2009:1–6.